AROG Pharmaceuticals

5420 LBJ Freeway
Suite #410
Dallas,  TX  75240

United States
http://www.arogpharma.com/
  • Booth: 22135

Arog Pharmaceuticals, LLC is developing CRENOLANIB, an orally bioavailable, mutant specific type I inhibitor of receptor kinases FLT3, PDGFRa, and PDGFRb. Crenolanib is currently in phase III development in AML and GIST.


  •  
  •      
     

  •  
  •